---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-142331"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:01:06.846257+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q1 net loss $14.8M; cash $292.5M; IND filings on track for 2022

## Summary
- Net loss of $14.8M in Q1 2022 vs $4.2M in Q1 2021, driven by higher R&D and G&A expenses.
- R&D expense $9.6M (up from $3.5M); G&A expense $5.2M (up from $0.7M).
- Cash and equivalents $292.5M as of March 31, 2022, supporting pipeline into clinical stage.
- IND for TYRA-300 (FGFR3 inhibitor) expected mid-2022; TYRA-200 (FGFR2) IND in H2 2022.
- Pipeline includes programs in achondroplasia, RET, and FGFR4-driven cancers.

## SEC filing metadata
- accession: 0001193125-22-142331
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312522142331/0001193125-22-142331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312522142331/d350831d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-142331
- JSON: https://secwatch.observer/filing/0001193125-22-142331.json
- Plain text: https://secwatch.observer/filing/0001193125-22-142331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.